Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target

Author: Benzinga Newsdesk | April 03, 2024 11:58am
Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $5 price target.

Posted In: APTO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist